Eli Lilly (LLY) Net Margin (2009 - 2026)
Eli Lilly posted quarterly Net Margin of 37.36% for Q1 2026, up 1568.0% year-on-year from 2.24% in Q1 2025, and up 8.57% on a QoQ basis from 34.41% in Q4 2025.
Eli Lilly (LLY) has 17 years of Net Margin data on file, last reported at 37.36% in Q1 2026.
- For the quarter ending Q1 2026, Net Margin rose 1568.0% year-over-year to 37.36%; the trailing twelve-month figure through Mar 2026 stood at 34.99% (up 1232.0% YoY), and the FY2025 full-year result was 31.67%, up 816.0% from the prior year.
- Net Margin for Q1 2026 stood at 37.36%, up from 34.41% in the prior quarter.
- Across five years, Net Margin topped out at 37.36% in Q1 2026 and bottomed at 0.6% in Q3 2023.
- The 5-year median for Net Margin is 24.36% (2022), against an average of 23.78%.
- The widest annual swing landed in 2023, when Net Margin slumped 2152 bps; it then surged 2323 bps in 2025.
- A 5-year view of Net Margin shows it stood at 26.54% in 2022, then decreased by 12 bps to 23.41% in 2023, then surged by 39 bps to 32.59% in 2024, then increased by 6 bps to 34.41% in 2025, then advanced by 9 bps to 37.36% in 2026.
- The last three Net Margin figures came in at 37.36% (Q1 2026), 34.41% (Q4 2025), and 31.72% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 37.36% |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 21.76% |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 4.65% |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | -25.84% |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 21.11% |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 29.04% |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | -0.56% |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 23.32% |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 37.36% |
| Dec 31, 2025 | 34.41% |
| Sep 30, 2025 | 31.72% |
| Jun 30, 2025 | 36.38% |
| Mar 31, 2025 | 21.67% |
| Dec 31, 2024 | 32.59% |
| Sep 30, 2024 | 8.48% |
| Jun 30, 2024 | 26.25% |
| Mar 31, 2024 | 25.58% |
| Dec 31, 2023 | 23.41% |
| Sep 30, 2023 | -0.60% |
| Jun 30, 2023 | 21.21% |
| Mar 31, 2023 | 19.32% |
| Dec 31, 2022 | 26.54% |
| Sep 30, 2022 | 20.91% |
| Jun 30, 2022 | 14.68% |
| Mar 31, 2022 | 24.36% |
| Dec 31, 2021 | 21.58% |
| Sep 30, 2021 | 16.39% |
| Jun 30, 2021 | 20.63% |
| Mar 31, 2021 | 19.91% |
| Mar 31, 2019 | 72.28% |
| Dec 31, 2018 | 0.07% |
| Sep 30, 2018 | 1.05% |
| Jun 30, 2018 | -0.51% |
| Mar 31, 2018 | 1.01% |
| Dec 31, 2017 | -25.15% |
| Sep 30, 2017 | 9.82% |
| Jun 30, 2017 | 17.31% |
| Mar 31, 2017 | -2.12% |
| Dec 31, 2016 | 13.40% |
| Sep 30, 2016 | 14.99% |
| Jun 30, 2016 | 13.83% |
| Mar 31, 2016 | 9.05% |
| Dec 31, 2015 | 8.55% |
| Sep 30, 2015 | 16.12% |
| Jun 30, 2015 | 12.07% |
| Mar 31, 2015 | 11.40% |
| Dec 31, 2014 | 8.08% |
| Sep 30, 2014 | 10.27% |
| Jun 30, 2014 | 14.86% |
| Mar 31, 2014 | 15.54% |
| Dec 31, 2013 | 12.36% |
| Sep 30, 2013 | 20.84% |
| Jun 30, 2013 | 20.34% |
| Mar 31, 2013 | 27.63% |
| Dec 31, 2012 | 13.74% |
| Sep 30, 2012 | 24.37% |
| Jun 30, 2012 | 16.49% |
| Mar 31, 2012 | 18.05% |
| Dec 31, 2011 | 14.29% |
| Sep 30, 2011 | 20.11% |
| Jun 30, 2011 | 19.15% |
| Mar 31, 2011 | 18.08% |
| Dec 31, 2010 | 18.90% |
| Sep 30, 2010 | 23.75% |
| Jun 30, 2010 | 24.13% |
| Mar 31, 2010 | 22.75% |
| Dec 31, 2009 | 15.43% |
| Sep 30, 2009 | 17.48% |
| Jun 30, 2009 | 21.89% |
| Mar 31, 2009 | 26.02% |